Table 3 Treatment-related adverse events.

From: Propensity score analysis of high-dose rate brachytherapy, immune checkpoint inhibitors, and docetaxel in second-line advanced NSCLC treatment

Event

Brachytherapy + ICIs + Docetaxel(n = 21)

ICIs + Docetaxel

(n = 21)

P

Any grade

Grade 1/2

Grade 3/4

Any grade

Grade 1/2

Grade 3/4

Any grade

Grade 1/2

Grade 3/4

Puncture site infection

2

2

0

0

0

0

0.311

0.311

Intrathoracic hemorrhage

3

3

0

0

0

0

0.144

0.144

Fatigue

3

3

0

1

1

0

0.293

0.293

Decreased appetite

4

3

1

2

1

1

0.372

0.292

> 0.999

Diarrhea

2

1

1

1

0

1

0.541

0.311

Fever

5

4

1

4

4

0

0.700

0.311

Hypertension

3

3

0

2

2

0

0.541

0.541

Pruritus

2

2

0

1

1

0

0.541

0.541

Rash

4

3

1

3

3

0

0.667

> 0.999

0.311

Proteinuria

3

3

0

2

2

0

0.632

0.632

Leukopenia

3

3

0

2

2

0

0.632

0.632

Thrombocytopenia

3

2

1

4

3

1

0.667

0.632

> 0.999

Reactive cutaneous capillary endothelial proliferation(Rccep)

2

1

1

1

1

0

0.541

0.311

Pneumothorax

2

2

0

0

0

0

0.144

0.144